The Proctitis drugs in development market research report provides comprehensive information on the therapeutics under development for Proctitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Proctitis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Proctitis and features dormant and discontinued products.
GlobalData tracks six drugs in development for Proctitis by five companies/universities/institutes. The top development phase for Proctitis is phase ii with four drugs in that stage. The Proctitis pipeline has six drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Proctitis pipeline products market are: BioCurity Pharmaceuticals, Shanghai Pharmaceuticals and Alfasigma.
The key targets in the Proctitis pipeline products market include DNA Directed RNA Polymerase Subunit Beta, Bacterial Cell Membrane, and Leukotriene Receptor.
The key mechanisms of action in the Proctitis pipeline product include Bacterial Cell Membrane Disruptor with one drug in Phase II. The Proctitis pipeline products include eight routes of administration with the top ROA being Rectal and two key molecule types in the Proctitis pipeline products market including Small Molecule, and Cell Therapy.
Proctitis overview
Proctitis is an inflammation in the lining of rectum. It can be chronic or acute. Causes of proctitis include IBD, sexually transmitted and gastrointestinal infections, radiation therapy, antibiotics, and NSAIDs. Some of the symptoms include anorectal pain; blood, mucus, or pus in the feces; swelling in the rectum; tenesmus (continuous feeling of bowel movement); dyschezia (painful bowel movements); and diarrhea or constipation. It can be diagnosed with the help of digital rectal examination, anoscopy, proctoscopy, flexible sigmoidoscopy, and blood test or culture tests for identifying infections. Treatment options vary depending on the cause. Antibiotics or antivirals can be used in case of infections, immunosuppressants for autoimmune related proctitis, and discontinuing use of a causative agent.
For a complete picture of Proctitis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
